IL-1 blockade for the topical treatment of ocular surface inflammatory disorders and the discovery of EBI-005, a novel IL-1 receptor inhibitor

References

• Market Scope. Comprehensive report on the global dry eye products market. Market Scope; St Louis, MO, USA: 2011
   Google Scholar
• International Dry Eye Workshop (DEWS) Report. Ocul Surf 2007;5:65-204
   Web of Science ®Google Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-22
   PubMed Web of Science ®Google Scholar
• Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28:43-58
   PubMed Web of Science ®Google Scholar
• Bielory BP, O’Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol 2012;90:399-407
   PubMed Web of Science ®Google Scholar
• Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Nature 2004;18:345-51
   Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
   PubMed Web of Science ®Google Scholar
• Zhu L, Shen J, Shang C, et al. Inflammatory cytokine expression on the ocular surface in the botulism toxin B inuduced murine dry eye model. Mol Vis 2009;15:250-8
   PubMed Web of Science ®Google Scholar
• Yoon KC, Park CS, You IC, et al. Expression of CSCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 2010;51:643-50
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Dana R, et al. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol 2010;3:425-42
   PubMed Web of Science ®Google Scholar
• Chen Y, Chauhan SK, Soo Lee H, et al. Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol 2013;7(1):38-45
   Google Scholar
• Saban DR, Calder V, Kuo C-H, et al. New twists to an old story: novel concepts in the pathogenesis of allergic eye disease. Curr Eye Res 2013;38:317-30
   PubMed Web of Science ®Google Scholar
• Keane–Myers AM, Miyazaki D, Liu G, et al. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 1999;40:3041-6
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012;130(1):90-100
   PubMedGoogle Scholar
• Pflugfelder SC, de Paiva CS, Li DQ, Stern ME. Epithelial–immune cell interaction in dry eye. Cornea 2008;27:S9-S11
   PubMed Web of Science ®Google Scholar
• Schein OD, Tielsch JM, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 1997;104:1395-401
   PubMed Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762-70
   PubMed Web of Science ®Google Scholar
• Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61
   PubMed Web of Science ®Google Scholar
• Ward KW. Superficial punctate fluorescein staining of the ocular surface. Optom Vis Sci 2008;85:8-16
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Baran I, Jacobs D. Corneal Pain without Stain: is it Real? Ocul Surf 2009;7:28-40
   PubMed Web of Science ®Google Scholar
• Belmonte C, Gallar J. Cold thermoreceptors, unexpected players in tear production and ocular dryness sensations. Invest Ophthalmol Vis Sci 2011;52:3888-92
   PubMed Web of Science ®Google Scholar
• Barbarino S, Shen LL, Chen L, et al. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005;46:2766-71
   Google Scholar
• Durson D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2002;43:632-8
   Google Scholar
• Chen Y-T, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren’s syndrome. Am J Pathol 2010;177:1333-43
   PubMed Web of Science ®Google Scholar
• Okanobo A, Chauhan S, Dastjerdi M, et al. New anti-inflammatory strategy to treat murine dry-eye disease. World Cornea Congress VI; 2010
   Google Scholar
• Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009;147(2):198-20
   PubMed Web of Science ®Google Scholar
• Okanobo A, Chauhan S, Dastjerdi M, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012;154:63-71
   PubMed Web of Science ®Google Scholar
• Vijmasi T, Chen F, Chen Y, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 2013;19:1957-65
   PubMed Web of Science ®Google Scholar
• Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013;131(6):715-23
   PubMed Web of Science ®Google Scholar
• Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361:184-7
   PubMed Web of Science ®Google Scholar
• Makelska H, Stein C. Immune mechanisms of pain and analgesia, in advances in experimental medicine and biology. 2003;521:40-50
   Google Scholar
• Viktovic L, Bockaert J, Jacque C. “Inflammatory” Cytokines: neuromodulators in Normal Brain? J Neurochem 2000;74:457-71
   Google Scholar
• Bletsa A, Fristad I, Berggreen E. Sensory pulpal nerve fibres and trigeminal ganglion neurons express IL-1RI: a potential mechanism for development of inflammatory hyperalgesia. Int Endod J 2009;42(11):978-86
   Google Scholar
• Fukuoka H, Kawatani M, Hisamitsu T, Takeshige C. Cutaneous hyperalgesia induced by peripheral injection of interleukin-1b in the rat. Brain Res 1994;657:133-40
   PubMedGoogle Scholar
• Gabay E, Wolf G, Shavit Y, et al. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain 2011;15:242-8
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32
   PubMed Web of Science ®Google Scholar
• Krause K, Metz M, Makris M, et al. The role of interleukin-1 in allergy-related disorders. Curr Opin Allergy Clin Immunol 2012;12:477-84
   PubMed Web of Science ®Google Scholar
• Schlereth S, Lee HS, Khandelwal P, Saban DR. Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. Am J Pathol 2012;180:2351-60
   PubMedGoogle Scholar
• Chung SH, Choi SH, Cho KJ, Joo CK. Toll-like receptor 4 signalling attenuates experimental allergic conjunctivitis. Clin Exp Immunol 2011;164:275-81
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Bielory L, Fischer A, et al. Animal models of allergic and inflammatory conjunctivitis. Allergy 2003;58:1101-13
   PubMedGoogle Scholar
• Guo Z, Zhang M, An H, et al. Fas ligation induces IL-1β-dependent maturation and IL-1β-independent survival of dendritic cells: different roles of ERK and NF-κB signaling pathways. Blood 2003;102:4441-7
   Google Scholar
• Chauhan SK and Dana R. Role of Th17 Cells in the immunopathogenesis of dry eye disease mucosal immunol. 2009;2(4):375-6
   Google Scholar
• Ben-Sasson SZ, Hu-Li J, Quiel J, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009;106:7119-24
   PubMed Web of Science ®Google Scholar
• Nako S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1β-induced corneal neovascularization. Am J Pathol 2007;171(3):1058-65
   Google Scholar
• Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res 2003;76:161-7
   PubMed Web of Science ®Google Scholar
• Zhu SN, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelim in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci 1999;40:1427-34
   PubMed Web of Science ®Google Scholar
• Dana MR, Zhu S, Yamada J. Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization. Cornea 1998;17:403-9
   PubMed Web of Science ®Google Scholar
• Dana MR. Angiogenesis and lymphangiogenesis – implications for corneal immunity. Semin Ophthalmol 2006;21(1):19-22
   Google Scholar
• Dana MR, Zhu S, Yamada J. Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization. Cornea 1998;17:403-9
   PubMed Web of Science ®Google Scholar
• Verhaeghe B, Gevaert P, Holtappels G, et al. Up-regulation of IL-18 in allergic rhinitis. Allergy 2002;57:825-30
   PubMed Web of Science ®Google Scholar
• Leonardi A, Borghesan F, DePaoli M, et al. Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjunctivitis. Exp Eye Res 1998;67:105-12
   PubMed Web of Science ®Google Scholar
• Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006;36(6):777-84
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory muckle-wells syndrome. Arthritis Rheum 2011;63:840-9
   PubMed Web of Science ®Google Scholar
• Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an Interleukin 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle–Wells and familial cold autoinflammatory syndromes. Rheumatology 2008;47:309-10
   PubMed Web of Science ®Google Scholar
• Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007;105:330-43
   PubMedGoogle Scholar
• Martin MU, Falk W. The interleukin-1 receptor complex and interleukin-1 signal transduction. Eur Cytokine Netw 1997;8:5-17
   PubMedGoogle Scholar
• Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3(105):cm1
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227
   PubMed Web of Science ®Google Scholar
• Schirmer EB, Golden K, Xu J, et al. Reduction of product-related species during the fermentation and purificationof a recombinant IL-1 receptor antagonist at the laboratory and pilot scale. Biotechnol J 2013;8:946-56
   Google Scholar
• Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci USA 2013;110(10):3913-18
   PubMed Web of Science ®Google Scholar
• Andreatta M, Schafer-Nielsen C, Lund O, et al. NNAlign: a web-basedprediction method allowing non-expert end-user discovery of sequence motifs in quantitative peptide data. 2011;6(11):e26781
   Google Scholar
• Furfine ES, Hou J, Collins K, et al. EBI-005: an interleukin-1 receptor inhibitor designed for the treatment of dry eye syndrome. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 2340
   Google Scholar
• Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000;243:147-54
   PubMed Web of Science ®Google Scholar
• Yang B, Baughman S, Sullivan J. Pharmacokinetics of anakinra in subjects with different levelsof renal function. Clin Pharmacol Ther 2003;74:85-94
   PubMed Web of Science ®Google Scholar
• Kineret® (anakinra) US Prescribing Information, Swedish Orphan Biovitrum AB (publ); 2012
   Google Scholar
• Gene Regulation. Available from: www.gene-regulation.com/images/ulrike6.png
   Google Scholar
• Furfine E, Collins K, Escobar D, et al. Preclinical Development of EBI-005: a Potent Interleukin-1 (IL-1) Receptor-1 (R1) Blocker for Topical Ocular Administration was Safe in GLP Toxicology Studies and Active in a Mouse Model of Dry Eye Disease (DED). RVO 2014 Poster C0058
   Google Scholar